MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Medicure Company Profile (CVE:MPH)

Consensus Ratings for Medicure (CVE:MPH) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: C$8.00

Analysts' Ratings History for Medicure (CVE:MPH)
Show:
DateFirmActionRatingPrice TargetActions
5/4/2016M PartnersReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/12/2016MackieBoost Price TargetBuyC$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Medicure (CVE:MPH)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for Medicure (CVE:MPH)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.13$0.13$0.13
Q2 20161$0.15$0.15$0.15
Q3 20161$0.16$0.16$0.16
Q4 20161$0.18$0.18$0.18
Q1 20171$0.26$0.26$0.26
Q2 20171$0.27$0.27$0.27
Q3 20171$0.29$0.29$0.29
Q4 20171$0.31$0.31$0.31
(Data provided by Zacks Investment Research)
Dividend History for Medicure (CVE:MPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Medicure (CVE:MPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/17/2016Albert David FriesenDirectorBuy1,100C$5.55C$6,105.00Tweet This Trade  Share This Trade on StockTwits
3/16/2016Graeme William MerchantInsiderBuy1,650C$6.40C$10,560.00Tweet This Trade  Share This Trade on StockTwits
3/11/2016Graeme William MerchantInsiderBuy1,500C$6.30C$9,450.00Tweet This Trade  Share This Trade on StockTwits
3/8/2016Graeme William MerchantInsiderSell6,300C$7.01C$44,163.00Tweet This Trade  Share This Trade on StockTwits
9/9/2015Elliott International CapitalInsiderSell1,426,002C$2.98C$4,249,485.96Tweet This Trade  Share This Trade on StockTwits
1/7/2015Albert David FriesenDirectorBuy2,900C$2.01C$5,829.00Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Medicure (CVE:MPH)
DateHeadline
02/24/16 09:28 AMMedicure Inc. (MPH.V) - Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapeutics in Canada, the United States, and Barbados. It primarily markets and sells AGGRASTAT injection, a glycoprotein GP IIb/IIIa ...
02/17/16 09:03 AMUndervalued And Underfollowed; Medicure Is My Favorite Pharma Small Cap - Medicure Inc. is a specialty pharmaceutical company founded in 1997 and headquartered in Winnipeg, Canada. It's stock is listed on the TSX Venture Exchange (MPH.V) and the OTC (OTCPK:MCUJF). Trading volume in the stock is underwhelming on both venues ...
01/22/16 08:43 AMMedicure To Present At Cantech Investment Conference - WINNIPEG, Jan. 21, 2016 /PRNewswire/ - Medicure Inc. (" Medicure" or the " Company") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, today announced that it will present at the 2016 Cantech Investment Conference on January 26 th in Toronto.
01/17/16 08:01 AMMedicure Inc V.MPH.H - A protocol of anticoagulation with tirofiban during flow diversion has an excellent safety profile. This protocol provides a reasonable alternative to pretreatment with aspirin and clopidogrel and is useful in patients with ruptured aneurysms or when the ...
About Medicure

Medicure Inc. (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company's primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company's United States subsidiary, Medicure Pharma, Inc. The Company is also engaged in the clinical development of TARDOXAL for neurological disorders. The Company's primary, non-AGGRASTAT research and development activity is TARDOXAL for the treatment of Tardive Dyskinesia (TD). The Company has completed Phase IIa stage of development for TARDOXAL. The Company is also developing Transdermal AGGRASTAT, a cure for acute cardiology. Transdermal AGGRASTAT is in preclinical-stage of development.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: CVE
  • Symbol: MPH
  • CUSIP:
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $N/A
  • 200 Day Moving Average: $N/A
  • P/E Ratio: N/A
  • P/E Growth: N/A
  • Market Cap: $N/A
  • Current Quarter EPS Consensus Estimate: $N/A EPS
Additional Links:
Medicure (CVE:MPH) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha